Exelixis' Cometriq rebounds with NSCLC data
This article was originally published in Scrip
Executive Summary
Exelixis's anticancer Cometriq has redeemed itself slightly following its major setback in the Phase III COMET-1 trial in prostate cancer with some promising Phase II data in non-small cell lung cancer, another major potential indication. Shares in the company were up by us much as 15% on the announcement to peak at $1.92 on 5 November on Nasdaq.